FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF

Stock Down By 79.9%

 
• By Ayisha Sharma
  
hand throwing ball of paper into wastebasket
FibroGen Is Scrapping Another Phase III Trial In IPF After The Failure • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D